Lifecore Biomedical (NASDAQ:LFCR) Issues Earnings Results, Beats Estimates By $0.02 EPS

Lifecore Biomedical (NASDAQ:LFCR) released its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02, Zacks reports. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%.

Lifecore Biomedical Trading Down 10.4 %

Shares of NASDAQ:LFCR traded down $0.77 during trading hours on Thursday, hitting $6.66. 832,670 shares of the company’s stock traded hands, compared to its average volume of 214,029. The firm has a market capitalization of $245.27 million, a P/E ratio of 83.25 and a beta of 0.99. The business has a fifty day moving average price of $6.96 and a 200-day moving average price of $5.77. Lifecore Biomedical has a 1 year low of $3.68 and a 1 year high of $8.90. The company has a debt-to-equity ratio of 12.90, a current ratio of 1.83 and a quick ratio of 0.80.

Analyst Ratings Changes

Separately, Craig Hallum upped their price target on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 22nd.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.